BGI Genomics Balance Sheet Health
Financial Health criteria checks 5/6
BGI Genomics has a total shareholder equity of CN¥10.0B and total debt of CN¥242.1M, which brings its debt-to-equity ratio to 2.4%. Its total assets and total liabilities are CN¥13.5B and CN¥3.4B respectively. BGI Genomics's EBIT is CN¥102.0M making its interest coverage ratio -2.7. It has cash and short-term investments of CN¥5.3B.
Key information
2.4%
Debt to equity ratio
CN¥242.08m
Debt
Interest coverage ratio | -2.7x |
Cash | CN¥5.26b |
Equity | CN¥10.04b |
Total liabilities | CN¥3.41b |
Total assets | CN¥13.46b |
Recent financial health updates
Is BGI Genomics (SZSE:300676) A Risky Investment?
Jul 15Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly
Mar 25Recent updates
Is BGI Genomics (SZSE:300676) A Risky Investment?
Jul 15Why Investors Shouldn't Be Surprised By BGI Genomics Co., Ltd.'s (SZSE:300676) Low P/S
May 22BGI Genomics' (SZSE:300676) Conservative Accounting Might Explain Soft Earnings
Apr 21Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly
Mar 25Financial Position Analysis
Short Term Liabilities: 300676's short term assets (CN¥7.8B) exceed its short term liabilities (CN¥3.1B).
Long Term Liabilities: 300676's short term assets (CN¥7.8B) exceed its long term liabilities (CN¥328.8M).
Debt to Equity History and Analysis
Debt Level: 300676 has more cash than its total debt.
Reducing Debt: 300676's debt to equity ratio has increased from 0% to 2.4% over the past 5 years.
Debt Coverage: 300676's debt is well covered by operating cash flow (128.6%).
Interest Coverage: 300676 earns more interest than it pays, so coverage of interest payments is not a concern.